Tissue Science Laboratories PLC: Appointments Of Financial Advisors And Brokers

14 June 2004

Tissue Science Laboratories plc (LSE:TSL), the medical devices company specialising in human tissue replacement and repair, is pleased to announce the appointments of Code Securities Limited as the Company's financial advisor and joint stockbroker, and Altium Capital Limited as the Company's nominated advisor and broker. The appointments become effective immediately.

Enquiries

TSL plc
Martin Hunt, Chief Executive		+44 (0)1252 333 002
Hogarth PR
Melanie Toyne Sewell		+44 (0)20 7357 9477
Code Securities Limited
Juliet Thompson		+44 (0)20 7024 2004

NOTES TO EDITORS
Founded in 1995 with headquarters in Aldershot, Hampshire, TSL is a medical technology company specialising in tissue repair and replacement with a proprietary sheet product derived from porcine dermis. TSL has launched successfully different formulations of the product and built a development pipeline that addresses the large and fast growing surgical implant market. The Company floated in November 2001 and is listed on the Alternative Investment Market.
TSL has a family of products based on the same core technology. Each product has been adapted, with unique properties, to make it suitable for use in different applications. Pelvicol/Permacol Surgical Implant (SI) is sold by Bard in the US and Europe for urology and gynaecology applications; Permacol SI (general surgery) is sold for complex hernia repair in the US and Europe; Permacol SI (ENT, plastic and reconstruction) is sold in Europe for head and face applications; Permacol Injection (UBA) is an injectable form of Permacol used as a urethral bulking agent to treat female stress incontinence. The Company has also recently signed a worldwide distribution agreement with Zimmer for the application of Permacol (SI) in the orthopaedic market. Further variations of the sheet and injectable forms of Permacol are being developed. Bard is a trademark of C.R. Bard, Inc. or an affiliate.

Code Securities Limited ("Code") is a newly formed London-based investment banking firm providing a full range of advisory, fundraising and stockbroking services for companies and investors in the European life sciences and medtech sectors. Code is is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.